Jasper Edgar Neggers,Bert Kwanten,Tim Dierckx,Hiroki Noguchi,Arnout Voet,Lotte Bral,Kristien Minner,Bob Massant,Nicolas Kint,Michel Delforge,Thomas Vercruysse,Erkan Baloglu,William Senapedis,Maarten Jacquemyn,Dirk Daelemans

Abstract:Unraveling the mechanism of action and molecular target of small molecules remains a major challenge in drug discovery. While many cancer drugs target genetic vulnerabilities, loss-of-function screens fail to identify essential genes in drug mechanism of action. Here, we report CRISPRres, a CRISPR-Cas-based genetic screening approach to rapidly derive and identify drug resistance mutations in essential genes. It exploits the local genetic variation created by CRISPR-Cas-induced non-homologous end-joining (NHEJ) repair to generate a wide variety of functional in-frame mutations. Using large sgRNA tiling libraries and known drug–target pairs, we validate it as a target identification approach. We apply CRISPRres to the anticancer agent KPT-9274 and identify nicotinamide phosphoribosyltransferase (NAMPT) as its main target. These results present a powerful and simple genetic approach to create many protein variants that, in combination with positive selection, can be applied to reveal the cellular target of small-molecule inhibitors.

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes